Skip to main content
Premium Trial:

Request an Annual Quote

Jennifer Cook, Catherine Friedman, Min Cui

Grail has appointed Jennifer Cook as CEO, effective Jan. 2, 2018. She will take over for Bill Rastetter, who has been serving as interim CEO. Rastetter will continue his role as chairman of the board of directors. Cook joins Grail from Roche, where she is currently head of clinical operations in product development for Roche Pharmaceuticals. Previously, she was head of the Europe region for Roche Pharmaceuticals, and has also held research and management positions at Genentech.

Grail has also appointed Catherine Friedman and Min Cui to its board of directors. Friedman is an independent financial consultant and previously held executive positions at investment bank Morgan Stanley, including as managing director and head of West Coast Healthcare and co-head of Biotechnology Practice. She is also on the board of directors at Altaba (formerly Yahoo!), Innoviva, and Radius Health. Cui is founder and managing director of Decheng Capital. He is also on the board of directors at AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, Ketai Medical, Levitas, and Sinomed. Previously, he was an investment partner at Bay City Capital and director of strategic investment for the Southern Research Institute.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.